Sulaiman Laila, Hesham Dina, Abdel Hamid Magdy, Youssef Ghada
Cardiology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Egypt Heart J. 2021 Mar 1;73(1):20. doi: 10.1186/s43044-021-00142-z.
Chemotherapeutic agents have many side effects; among them is cardiotoxicity. Ejection fraction fails to detect the subtle alterations of left ventricular (LV) function; that is why there is a need for a more sensitive tool. The aim is to detect subclinical LV systolic dysfunction after chemotherapeutic treatment, using NT-BNP plasma level as well as speckle tracking echo-global longitudinal strain (STE-GLS). Seventy-four asymptomatic, non-metastasizing breast cancer female patients without risk factors were included. They were assessed before and 6 weeks after taking their first chemotherapeutic session. Assessment included clinical characteristics, conventional two-dimensional (2D) and three-dimensional (3D) echocardiography, and 2D STE-GLS. Blood samples for NT-BNP plasma level were collected on both visits and were later analyzed using a Sandwich ELISA technique.
The median NT-proBNP almost doubled after 6 weeks of chemotherapy (73.50 vs 34.4 pg/L, p value <0.001). Only two patients showed significant reduction of LVEF >10% to less <55%. One patient died before her scheduled follow-up visit, and the cause of death is unknown. Fifty patients showed elevated follow-up levels of the NT-BNP. As compared to the baseline visit, 12 patients had a high relative reduction of the LV-GLS (>15%) and all of them had a relatively higher NT-proBNP. A 2.2 relative elevation of the NT-proBNP was able to define a relative reduction of LV-GLS >15% by a 100% sensitivity and 81.8% specificity.
The relative reduction of LV-GLS and the relative elevation of NT-proBNP were successful in defining subclinical, subtle chemotherapy-induced cardiotoxicity after 6 weeks of the first chemotherapeutic agent administration.
化疗药物有许多副作用,其中包括心脏毒性。射血分数无法检测左心室(LV)功能的细微变化,这就是需要一种更敏感工具的原因。目的是使用NT-BNP血浆水平以及斑点追踪超声心动图-整体纵向应变(STE-GLS)检测化疗后亚临床左心室收缩功能障碍。纳入了74例无危险因素的无症状、非转移性乳腺癌女性患者。在她们接受第一次化疗疗程之前和之后6周进行评估。评估包括临床特征、传统二维(2D)和三维(3D)超声心动图以及二维STE-GLS。在两次就诊时均采集用于检测NT-BNP血浆水平的血样,随后使用夹心ELISA技术进行分析。
化疗6周后,NT-proBNP的中位数几乎翻倍(73.50对34.4 pg/L,p值<0.001)。只有两名患者的左心室射血分数(LVEF)显著降低>10%至<55%。一名患者在预定的随访就诊前死亡,死因不明。50例患者的NT-BNP随访水平升高。与基线就诊相比,12例患者的左心室整体纵向应变(LV-GLS)相对降低>15%,并且他们所有人的NT-proBNP相对较高。NT-proBNP相对升高2.2能够以100%的敏感性和81.8%的特异性定义LV-GLS相对降低>15%。
在首次给予化疗药物6周后,LV-GLS的相对降低和NT-proBNP的相对升高成功地定义了亚临床、细微的化疗所致心脏毒性。